Aldeyra Therapeutics, Inc.
ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.52
Price+1.33%
$0.02
1Y
Price
Market Cap
$91.688m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$27.370m
+19.1%
1y CAGR+3.3%
3y CAGR+12.3%
5y CAGREPS
-$0.46
+17.9%
1y CAGR+3.8%
3y CAGR+12.8%
5y CAGRBook Value
$42.157m
$66.483m
Assets$24.326m
Liabilities$15.513m
DebtDebt to Assets
23.3%
-0.6x
Debt to EBITDAFree Cash Flow
-$25.986m
+22.1%
1y CAGR+0.8%
3y CAGR+12.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company